Codiak BioSciences, Inc. (CDAK)
| Market Cap | 482.71M |
| Revenue (ttm) | 622 |
| Net Income (ttm) | -94.46M |
| Shares Out | 18.59M |
| EPS (ttm) | -5.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $26.60 |
| Previous Close | $25.87 |
| Change ($) | 0.73 |
| Change (%) | 2.82% |
| Day's Open | 25.72 |
| Day's Range | 25.17 - 27.90 |
| Day's Volume | 104,273 |
| 52-Week Range | 7.90 - 32.30 |
– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –
– exoIL-12 resulted in no local or systemic treatment-related adverse events –
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a n...
– Human clinical testing now underway with Codiak's first two candidates, exoIL-12™ and exoSTING™ –
– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo –
Nine IPOs and five SPACs went public this past week, and one IPO postponed.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Codiak BioSciences, Inc. (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines...
About CDAK
Codiak BioSciences is harnessing exosomes?natural intercellular messengers?to pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including i... [Read more...]
| Industry Biotechnology | IPO Date Oct 14, 2020 |
| CEO Douglas Williams | Employees 101 |
| Stock Exchange NASDAQ | Ticker Symbol CDAK |
Analyst Forecasts
According to 4 analysts, the average rating for CDAK stock is "Strong Buy." The 12-month stock price forecast is 35.00, which is an increase of 31.58% from the latest price.